ImmunityBio Inc Aktie News

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström's Macroglobulinemia. The outpatient study eval...

Expand NASDAQ: IBRX ImmunityBio Today's Change (-3.72%) $-0.24 Current Price $6.21 Key Data Points Market Cap $6.4B Day's Range $6.16 - $6.75 52wk Range $1.83 - $8.28 Volume 37M Avg Vol 23M Gross Margin 80.41% ImmunityBio (IBRX 3.72%), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKT...

Expand NASDAQ: IBRX ImmunityBio Today's Change (-12.13%) $-0.89 Current Price $6.45 Key Data Points Market Cap $7.2B Day's Range $6.43 - $7.88 52wk Range $1.83 - $8.28 Volume 75M Avg Vol 22M Gross Margin 80.41% ImmunityBio (IBRX 12.13%), an immunity-focused biotech, closed Friday's session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progress...

Expand NASDAQ: IBRX ImmunityBio Today's Change (6.79%) $0.44 Current Price $6.92 Key Data Points Market Cap $6.4B Day's Range $5.71 - $7.10 52wk Range $1.83 - $7.98 Volume 96M Avg Vol 19M Gross Margin 80.41% ImmunityBio (IBRX +6.79%), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what t...

Expand NASDAQ: IBRX ImmunityBio Today's Change (17.39%) $0.96 Current Price $6.48 Key Data Points Market Cap $5.4B Day's Range $6.08 - $7.98 52wk Range $1.83 - $7.98 Volume 210M Avg Vol 16M Gross Margin 80.41% ImmunityBio (IBRX +17.39%), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for AN...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company's supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladd...

Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.